This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The findings suggest that the fibroblast growth factor receptor 2b (FGFR2b)-targeted monoclonal antibody bemarituzumab plus chemotherapy provided a statistically significant and clinically meaningful improvement in overall survival. The post What will shape the Pharma landscape in Q3 2025?
Published July 8, 2025 By Kelly Bilodeau post share post print email license Stock via Getty Images Listen to the article 5 min This audio is auto-generated. The results marked a major step for a disease with a 67% six-month survival rate using standard chemotherapies. By Amy Baxter • July 7, 2025 Keep up with the story.
The Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations 2025 reduces waiting times and boosts access to innovative therapies, MHRA explained. These therapies, such as CAR-T cancer therapy, have previously been produced in specialist facilities often far away from patients, resulting in treatment delays.
Published June 6, 2025 Michael Gibney Senior Editor & Writer post share post print email license Permission granted by Daiichi Sankyo Listen to the article 8 min This audio is auto-generated. At ASCO, one of the most talked-about studies was a late-stage trial in which the treatment outperformed chemotherapy as a first-line drug.
Based on the FDA clearance, the company anticipates the commencement of Phase I clinical trials for ALX2004 in mid-2025. We meticulously designed all aspects of ALX2004 the antibody backbone, linker and payload to optimise the targeted delivery of a powerful chemotherapy payload to tumour cells while minimising systemic toxicity.
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, showcased significant advances across a range of malignancies, with novel agents, biomarker-driven strategies, and long-term outcomes data offering new insights into cancer treatment with implications for pharmacy practice. months; HR, 0.60; 95% CI, 0.47-0.77);
The company aims to reduce the toxic effects of chemotherapy and chances of cancer relapse improving the quality of lives of patients suffering from cancer. By 2025, the contribution of the Indian biotechnology industry to the global biotechnology market is expected to grow to 19 per cent.
On January 16, 2025, the FDA approved acalabrutinib (Calquence; AstraZeneca) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). January 16, 2025. Accessed May 14, 2025.
A retrospective study presented at the American Society of Health-System Pharmacists 2025 Pharmacy Futures meeting has revealed significant variability in asthma treatment regimens following initial diagnosis, with many patients not receiving care aligned with the Global Initiative for Asthma (GINA) recommendations. Accessed June 9, 2025.
Accessed May 5, 2025. Accessed May 5, 2025. Accessed May 5, 2025. Wick, MBA, RPh, FASCP Key Takeaways Pharmacists can address SDOH by providing patient-centered care, promoting immunizations, and offering point-of-care testing to improve health outcomes. REFERENCES 1. Social determinants of health. Healthy People 2030.
Soefje, PharmD, MBA, BCOP, during the Hematology/Oncology Pharmacy Association (HOPA) 2025 Annual Conference in Portland, Oregon. Presented at: Hematology/Oncology Pharmacy Association 2025 Annual Conference; April 9-12, 2025; Portland, OR. That’s the system we are headed into very rapidly.” REFERENCE Soefje SA.
SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations.
Pharmacy Times : Can you share what you presented at the 2025 OPC meeting? Heidi Finnes, PharmD, BCOP, FHOPA : I shared new hope in cutaneous malignancies and abstracts from the 2025 ASCO meeting. Heidi Finnes, PharmD, BCOP, FHOPA : I shared new hope in cutaneous malignancies and abstracts from the 2025 ASCO meeting.
Clinical Applications and Economic Impacts Biologics have significantly impacted cancer therapies by targeting cancer cells more specifically and reducing adverse events compared with traditional chemotherapy, Darkow noted. Presented at: American Association of Pharmacy Technicians 2025 Annual Pharmacy Technician Convention.
A man aged 55 years with metastatic colorectal cancer was initiated on a standard fluoropyrimidine-based chemotherapy regimen. While the European Medicines Agency mandated pre-treatment DPD testing in Europe as early as 2020, and the UK’s National Health Service followed suit the same year, the US only reached a consensus in 2025.
Benmelstobart (TQB2450; Chia Tai Tianqing Pharmaceutical Group Co, Ltd) in combination with chemotherapy followed by sequential combination with anlotinib (Catequentinib; Advenchen Laboratories) led to significant improvements in progression-free survival (PFS), with a manageable safety profile. months versus 7.79 months with tislelizumab.
Accessed May 15, 2025. Accessed May 15, 2025. Accessed May 15, 2025. Accessed May 15, 2025. Related Videos Related Content Advertisement June 20th 2025 OTC Case Studies: Summer Skin Care Sneha Baxi Srivastava, PharmD, BCACP, CDCES, DipACLM, FADCES Rupal Patel Mansukhani, PharmD, FAPhA, NCTTP June 3rd 2025 S2.
Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy.
Although improved clinical outcomes with the addition of chemotherapy to ICI have been recorded for some patients, there is ongoing research to understand how prognostic factors (eg, smoking history, tumor histology, performance status) can provide some predictive values for patient response to ICI therapy. July 7, 2025. News release.
At the 2025 American Society of Health-System Pharmacists Pharmacy Futures meeting, Esther E. Presented at: American Society of Health-System Pharmacists 2025 Pharmacy Futures. Charlotte, NC; June 9, 2025. Accessed June 9, 2025. Newman TV, San-Juan-Rodriguez A, Parekh N, et al. Subscribe Now!
June 10, 2025. Accessed June 10, 2025. Related Videos Related Content Advertisement June 10th 2025 Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems Aislinn Antrim, Managing Editor June 3rd 2025 S2. PR Newswire. Meloxicam: Selective COX-2 inhibition in clinical practice.
SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. The abstract was originally shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. HOPA has selected 4.0 Additional information is available here.
Pharmacy Times : Can you share what you presented at the 2025 OPC meeting? Yes, we currently have antibody-drug conjugates that are conjugated to a cytotoxic chemotherapy. Pharmacy Times : Can you share your experience at OPC 2025 and the significance of these meetings for pharmacists? We look at ADCs. Subscribe Now!
Pharmacy Times : Can you share what you presented at OPC 2025? So I think the study really showed the benefit of remote clinical monitoring after starting chemotherapy. Eugene Przespolewski, PharmD, BCOP, DPLA : At OPC, I presented a few different topics, really focused on care models and optimization.
2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025. Accessed January 17, 2025. Accessed February 2025. March 6, 2025. Accessed May 12, 2025. Accessed January 15, 2025. Accessed January 15, 2025. Accessed January 15, 2025. Accessed January 20, 2025.
SHOW MORE Nivolumab (Opdivo) and chemotherapy demonstrated an overall survival benefit at 5 years, affirming its role as a standard of care option. 1,2 Nivolumab and chemotherapy is a standard of care option for resectable non-small cell lung cancer. months with the combination of nivolumab and chemotherapy, and 24.0%
I recently had the opportunity to blend my own science and philosophy at the Hematology/Oncology Pharmacy Association (HOPA) 2025 Annual Conference in Portland, Oregon, presenting on psychedelic medicines in oncology and palliative care. Potential Roles of the Oncology Pharmacist My friend died of his metastatic cancer in early 2025.
Vitamin D supplementation increased 25-hydroxyvitamin-D levels significantly, suggesting a potential role in enhancing chemotherapy effectiveness. The study's findings support further research with larger samples to explore vitamin D's impact on chemotherapy and breast cancer remission likelihood.
I think it’ll be chemotherapy—maybe their cells being given outpatient—and then, as we hit their hardest time or their highest risk for either febrile neutropenia or mucositis or even some of the toxicities from the chemotherapy, we have them inpatient until we feel comfortable, and then transition it so that it could be all outpatient.
Completion Date (Estimated): December 31, 2025 TRUST-II Trial Name: Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II) ClinicalTrials.gov ID: NCT04919811 Sponsor: Nuvation Bio Inc. Additionally, patients may have received prior chemotherapy for advanced disease. June 11, 2025. Accessed June 11, 2025.
At the 2025 American Society of Health-System Pharmacists (ASHP) Pharmacy Futures meeting, 4 pharmacy leaders from major health systems gathered for a candid panel discussion about the rapidly evolving role of pharmacists in managing advanced therapeutics, including cell and gene therapies. Accessed June 9, 2025.
Frankie Fattorini July 1, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The EU Pharma Package’s attempt to balance priorities risks achieving none. Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Photo by SvetaZi/iStock via Getty Images.
Results will be shared at the 2025 Oncology Pharmacists Connect meeting, potentially aiding oncology pharmacists in refining treatment strategies for sAML. SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. HOPA has selected 4.0
Mok : Right now, we have a lot of chemotherapy being used, but there are many more novel treatments being studied, especially in earlier lines of treatment. Bispecifics are moving up in the lymphoma space, and these newer therapies may have some synergistic effects with chemotherapy. Accessed June 19, 2025. Updated May 11, 2025.
HLX22 is the first anti-HER2 targeted treatment to receive ODD from both the US Food and Drug Administration (FDA) in March 2025 and from the EU. An international multicentre Phase III clinical study (HLX22-GC-301) investigated HLX22 combined with trastuzumab and chemotherapy as a first-line therapy for HER2-positive advanced gastric cancer.
Robert Barrie July 4, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Only 4% of global drugs sales in 2030 will have patent protection. Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. LanKS via Shutterstock. Find out more Sign up for our daily news round-up!
Updated June 18, 2025. Accessed June 18, 2025. Jim Ruble, PharmD, JD June 3rd 2025 S2. Jim Ruble, PharmD, JD June 3rd 2025 S2. CNN Health. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!
July 1, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The therapy can be administered either intravenously or subcutaneously. Credit: HenadziPechan/Shutterstock. By GlobalData Learn more about Strategic Intelligence Gammagard liquid ERC is approved under the brand name Deqsiga by the European Medicines Agency.
TRE-515 Combined With a Radiopharmaceutical As a precision cancer treatment designed for adults with PSMA-positive mCRPC, lutetium Lu 177 vipivotide tetraxetan is used after individuals have undergone other treatments like androgen receptor pathway inhibition and taxane-based chemotherapy. July 9, 2025. Accessed July 10, 2025.
Theramex and SMC both made the announcement on July 7, 2025, with SMC additionally publishing advice on seven other medicines (1,2). July 7, 2025. July 2025 Decisions News Release. July 7, 2025. Meeting Highlights from the Committee for Medicinal Products for Human Use (CHMP) 24–27 February 2025. Press Release.
July 4, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Vevzuo is authorised to prevent bone complications in adults with advanced cancer in bone and treat GCT of bone. The decision by the EC follows the Committee for Medicinal Products for Human Use’s (CHMP) positive recommendation issued in April 2025.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content